Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Saito, Keita ^a   Matsumoto, Shingo ^a   Yasui, Hironobu ^a,b   Devasahayam, Nallathamby ^a   Subramanian, Sankaran ^a   Munasinghe, Jeeva P ^c   Patel, Vyomesh ^d   Gutkind, J Silvio ^d   Mitchell, James B ^a   Krishna, Murali C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CARCINOGENESIS; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; PERICYTE; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; DIAGNOSTIC IMAGING; ELECTRON SPIN RESONANCE SPECTROSCOPY; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C3H; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

MAMMALIA; MURINAE; MUS;

EID: 84869743247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049456     Document Type: Article

References (42)

1. Mao L, Hong WK, Papadimitrakopoulou VA, (2004) Focus on head and neck cancer. Cancer Cell 5: 311-316.
2. Hunter KD, Parkinson EK, Harrison PR, (2005) Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135.
3. Nicholson KM, Anderson NG, (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395.
4. Luo J, Manning BD, Cantley LC, (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262.
5. Brader S, Eccles SA, (2004) Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 2-8.
6. Brazil DP, Yang ZZ, Hemmings BA, (2004) Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242.
7. Bjornsti MA, Houghton PJ, (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
8. Easton JB, Houghton PJ, (2006) mTOR and cancer therapy. Oncogene 25: 6436-6446.
9. Guertin DA, Sabatini DM, (2007) Defining the Role of mTOR in Cancer. Cancer Cell 12: 9-22.
10. Abraham RT, Eng CH, (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 12: 209-222.
11. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, et al. (2005) Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65: 9953-9961.
12. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, et al. (2008) Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68: 6598-6607.
13. Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS, (2008) A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res 68: 1144-1153.
14. Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM, et al. (2011) Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol Cancer Ther 10: 1173-1184.
15. Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, et al. (2000) Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 60: 4556-4560.
16. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, et al. (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570.
17. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
18. Zhou Q, Guo P, Gallo JM, (2008) Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 14: 1540-1549.
19. Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, et al. (2011) Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 71: 6350-6359.
20. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, et al. (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24: 5414-5422.
21. Yasui H, Matsumoto S, Devasahayam N, Munasinghe JP, Choudhuri R, et al. (2010) Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res 70: 6427-6436.
22. Matsumoto K, Subramanian S, Devasahayam N, Aravalluvan T, Murugesan R, et al. (2006) Electron paramagnetic resonance imaging of tumor hypoxia: enhanced spatial and temporal resolution for in vivo pO2 determination. Magn Reson Med 55: 1157-1163.
23. Matsumoto S, Hyodo F, Subramanian S, Devasahayam N, Munasinghe J, et al. (2008) Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest 118: 1965-1973.
24. Saito K, Matsumoto S, Devasahayam N, Subramanian S, Munasinghe JP, et al. (2012) Transient decrease in tumor oxygenation after intravenous administration of pyruvate. Magn Reson Med 67: 801-807.
25. Suit HD, Maimonis P, Michaels HB, Sedlacek R, (1981) Comparison of hyperbaric oxygen and misonidazole in fractionated irradiation of murine tumors. Radiat Res 87: 360-367.
26. Suit HD, Suchato C, (1967) Hyperbaric oxygen and radiotherapy of a fibrosarcoma and of a squamous-cell carcinoma of C3H mice. Radiology 89: 713-719.
27. Fu KK, Rayner PA, Lam KN, (1984) Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 10: 1473-1478.
28. Devasahayam N, Subramanian S, Murugesan R, Cook JA, Afeworki M, et al. (2000) Parallel coil resonators for time-domain radiofrequency electron paramagnetic resonance imaging of biological objects. J Magn Reson 142: 168-176.
29. Subramanian S, Devasahayam N, Murugesan R, Yamada K, Cook J, et al. (2002) Single-point (constant-time) imaging in radiofrequency Fourier transform electron paramagnetic resonance. Magn Reson Med 48: 370-379.
30. Devasahayam N, Subramanian S, Murugesan R, Hyodo F, Matsumoto K, et al. (2007) Strategies for improved temporal and spectral resolution in in vivo oximetric imaging using time-domain EPR. Magn Reson Med 57: 776-783.
31. Hyodo F, Chandramouli GV, Matsumoto S, Matsumoto K, Mitchell JB, et al. (2009) Estimation of tumor microvessel density by MRI using a blood pool contrast agent. Int J Oncol 35: 797-804.
32. Dharmaraj CD, Thadikonda K, Fletcher AR, Doan PN, Devasahayam N, et al. (2009) Reconstruction for time-domain in vivo EPR 3D multigradient oximetric imaging-a parallel processing perspective. Int J Biomed Imaging 2009: 528639.
33. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, et al. (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13: 4964-4973.
34. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, et al. (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15: 1612-1622.
35. Guertin DA, Sabatini DM, (2005) An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361.
36. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
37. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135.
38. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, et al. (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66: 10040-10047.
39. de Lussanet QG, Langereis S, Beets-Tan RG, van Genderen MH, Griffioen AW, et al. (2005) Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 235: 65-72.
40. Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, et al. (2006) Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol Cancer Ther 5: 1950-1957.
41. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, et al. (2009) Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 15: 589-596.
42. Fokas E, Im JH, Hill S, Yameen S, Stratford M, et al. (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72: 239-248.